Publication Type:

Journal Article

Source:

Nanomedicine, Future Medicine, Volume 9, Number 18, p.2721–2723 (2014)

URL:

http://www.futuremedicine.com/doi/full/10.2217/nnm.14.181

Abstract:

Breast cancer is reported to be the most frequent cancer type in women worldwide, with approximately 1.7 million newly diagnosed cases reported in 2012. During their lifetime, approximately 12% of women in the USA will develop invasive breast cancer, the second leading cause of cancer death of women in the USA [1]. In India, 1000,000 new cases of breast cancer are being reported every year [2]. Both local and systemic therapies are available for breast cancer now. Current treatment methods for breast cancer include invasive surgical procedures, radiotherapy, hormone therapy and chemotherapy. These therapies are less effective and recurrence is still a major problem in breast cancer patients. These therapies impart severe side effects and significant toxicity to normal cells [3]. A minimally invasive local delivery system capable of delivering one or a combination of drugs may overcome risks associated with surgery and also reduce the toxicity of anticancer drugs to normal cells/tissues.

Nanogel holds promise as one of the best drug-delivery systems owing to its water solubility, biocompatibility, excellent encapsulation stability and ease to synthesize. Nanogels also respond well to biological stimuli. Various possibilities of using nanogels exist in cancer therapeutics as unlike other commonly available cancer chemotherapeutic drugs used in the clinic, which target cancer cells from outside, nanogels can be effectively used to functionalize with ligands and that in turn helps in cancer cell targeting [4–6].

For carrying therapeutic moieties for cancer, the usage of macromolecules such as fibrin and fibrinogen are gaining interest nowadays. Fibrin glue has been exploited in carrying methotraxate, which showed considerable potential in shrinking tumors in glioblastoma in vivo. Fibrinogen-bound methotrexate therapy in vivo was described for Gardner lymphosarcoma in mice. Fibrinogen-methotrexate conjugate showed significant in vivo anti-tumor activity compared with that of free methotrexate and thus suggested the therapeutic utility of these potential drug conjugates [7]. Jakate et al. reported docetaxel-loaded olive oil droplet coated with fibrinogen useful for taxane-sensitive fibrin-rich tumors by facilitating the retention of these droplets in the tumor microenvironment. They reported improvement in the median survival time of B16F10 melanoma bearing mice compared with the free taxotere treatment [8].

In the last few years, many researchers have reported the use of this nanoformulated natural protein as a drug cargo for cancer. Sanoj et al. (2010) reported the fabrication of biocompatible fibrinogen nanoparticle (FNP) using simple co-acervation method. The 150 nm-sized fibrinogen nanoparticles was taken up efficiently by the cancer cells and nontoxic to an array of cancer and normal cell lines. FNPs were also found to be hemocompatible and biocompatible in vitro [9].

These fibrinogen nanoparticles were used for delivering anticancer agents like curcumin (CRC), a potent phytochemical and 5-flurouracil (5-FU), a pyramidine analog. CRC-FNPs and 5-FU-FNPs exhibited controlled and sustained release of these drugs in vitro and induced toxicity toward breast cancer cell lines (MCF-7). The tumor-accumulating property of fibrinogen is utilized and hence advantageous for delivering these anticancer therapeutic agents [10,11]. There are reports regarding the peptides binding to the irradiated tumor microvasculature and hence conjugation of these peptides to various carrier systems aid in tumor targeted drug delivery. The affinity of fibrinogen to integrin receptors has been studied in B16F0 tumors. Fibrinogen nanoparticles and liposomes were found to selectively bind within irradiated tumor blood vessels. The study reported the binding of fibrinogen-conjugated nanoparticles to radiation-activated receptors, reduced tumor blood flow and showed significant delayed and regressed tumor growth [12,13]. The above-mentioned micronized olive oil droplet with docetaxel and fibrinogen coating was also found to be effective against TA3/St mammary tumor grown in ascites [8].

Now researchers are thinking of stimuli-sensitive nanosystems for the efficient release of drugs to the target. Nanogels containing water within their structures hold promise in biomedical applications due to their responsiveness to temperature [13,14]. Fibrinogen was again exploited in thermo-responsive delivery of breast cancer drugs like megestrol acetate (Meg) in targeted fashion. Thermo-responsive polymer-like poly(N-isopropylacrylamide) (PNIPAAm) with a lower critical solution temperature (LCST) in the range of 30–32°C was grafted with fibrinogen and nanoformulated into nanogels with a combination of 5-FU/Meg drugs loaded within. Here the affinity of fibrinogen to interact with α5β1Integrin receptors overexpressed on various cancer cells including breast cancer cells has been reported. Thus 5-FU/Meg-loaded-fib-graft-PNIPAAm NGs preferentially target and deliver the therapeutic agents to breast cancer cells. Similarly, fibrinogen-graft-Poly(N-vinyl caprolactam) loaded with these dual drugs were reported to have efficient delivery properties toward breast cancer cells in vitro [15,16].

Fibrinogen-based nanosystems can be utilized not only for therapy but also for imaging purposes as well. A multifunctional fibrinogen nanoparticle was reported by Sanoj et al. for simultaneous therapy and imaging of breast cancer cells in vitro [17]. They have loaded a potent chemotherapeutic agent paclitaxel to fibrinogen-coated CdTe/ZnTe quantum dots (QDs) that aid in cancer cell imaging. Fibrinogen coating has significantly reduced the toxicity induced by the bare QDs which make it more cytocompatible and also provide α5β1Integrin receptor targeting to breast cancer cells. α5β1 +ve cancer cells like MCF-7 and Hela cells showed significant localization of these fibrinogen-coated-QDs compared with that of α5β1-ve L929 and HT-29 cells. So the synthesized paclitaxel-fibrinogen-coated yellow QDs were reported to have a bifunctional, imaging and therapeutic effect on breast cancer cells [17].

Cite this Research Publication

M. Sreerenganathan, Mony, U., and Dr. Jayakumar Rangasamy, “Thermo-responsive Fibrinogen Nanogels: a Viable Thermo-responsive Drug Delivery Agent for Breast Cancer Therapy?”, Nanomedicine, vol. 9, pp. 2721–2723, 2014.